Filing Flows › ClearPoint Neuro (CLPT) › Q2 2026
ClearPoint Neuro (CLPT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
ClearPoint Neuro (CLPT) reported revenue of $10.9M for the second quarter 2026 (Q2 2026), +18% from a year earlier and -10% from the quarter before. Operating margin was -94.2%, net loss $11.3M (104.2% of revenue).
ClearPoint Neuro, Q2 2026: revenue $10.9M (+18% year over year), operating margin -94.2%, net loss $11.3M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.9M | -10% | +18% |
| Operating profit | −$10.2M | — | — |
| Net earnings | −$11.3M | — | — |
| Operating cash flow | −$7.0M | — | — |
What changed
Revenue was $10.9M in Q2 2026, up 18% year over year and down 10% from the previous quarter. Neurosurgery Navigation and Therapy Disposable Products was the largest line at 51% of revenue. Neurosurgery Navigation and Therapy Disposable Products added $2.1M year over year (up 62%), 127% of the total change. Biologics and Drug Delivery Disposable Products declined 50%.
Gross margin was 61.7%, up 1.4 points from Q2 2025. Operating costs exceeded revenue by $10.2M, an operating margin of -94.2%. Operating expenses grew 51% against revenue growth of 18%. The fastest-growing cost line was Other operating costs (+68%). The quarter ended with a net loss of $11.3M, wider than the previous quarter's $9.6M loss.
Operating cash flow was −$7.0M. Non-cash charges added back $150K of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items added $1.9M. Capital expenditures of $214K exceeded it, leaving free cash flow of −$7.2M.
Questions
What was ClearPoint Neuro's revenue in the second quarter 2026?
ClearPoint Neuro (CLPT) reported revenue of $10.9M for the second quarter 2026 (Q2 2026), +18% from a year earlier and -10% from the quarter before.
Was ClearPoint Neuro profitable in the second quarter 2026?
Operating loss was $10.2M (-94.2% of revenue) and net loss $11.3M.
Source: ClearPoint Neuro 10-Q on SEC EDGAR.